Stephen Bloom, MD
Cardiovascular Disease · Overland Park, KSNPI 1972552552
Payments from drug & device makers
Across 329 payments — averaging $2329.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$358K
- Amgen$148K
- Cleerly, Inc.$105K
- Boehringer Ingelheim Pharma GmbH & Co.kg$46K
- CSL Behring$37K
- Boehringer Ingelheim International GmbH$29K
- plus $44K from 29 others
What the payments were for
- Food & beverage$4,508100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 28 | $357,945 |
| Amgen | 38 | $148,467 |
| Cleerly, Inc. | 12 | $105,111 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $45,543 |
| CSL Behring | 21 | $36,700 |
| Boehringer Ingelheim International GmbH | 10 | $28,650 |
| Bayer | 12 | $14,927 |
| Heartflow, Inc. | 6 | $9,692 |
| GE HealthCare | 5 | $8,293 |
| Boehringer Ingelheim | 11 | $7,472 |
| Pfizer | 24 | $700 |
| Johnson & Johnson | 42 | $493 |
| Sanofi-aventis U.S. LLC | 21 | $323 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $310 |
| Boston Scientific | 8 | $307 |
| Irhythm Technologies, Inc. | 10 | $215 |
| AstraZeneca | 11 | $213 |
| E.r. Squibb & Sons, L.L.C. | 3 | $138 |
| Daiichi Sankyo Inc. | 1 | $96 |
| Novo Nordisk | 5 | $91 |
| Regeneron Healthcare Solutions, Inc. | 5 | $83 |
| Kestra Medical Technology Services, Inc. | 4 | $81 |
| Alnylam Pharmaceuticals Inc. | 4 | $57 |
| Actelion Pharmaceuticals US, Inc. | 3 | $50 |
| Philips North America LLC | 3 | $48 |
| Lemaitre Vascular, Inc. | 2 | $44 |
| Abbott | 2 | $41 |
| Amarin Pharma, Inc. | 3 | $40 |
| Recor Medical Inc | 1 | $29 |
| Akcea Therapeutics, Inc. | 1 | $27 |
| Bolton Medical Inc | 1 | $23 |
| Medtronic | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Cvrx, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cleerly Ischemia$166
- Cleerly Labs$166
- WATCHMAN Access System$149
- Repatha$118
- VYNDAQEL$110
- CAMZYOS$109
- VYNDAMAX$101
How this compares
$766,273 in reported general payments places this provider in the 95th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 198 | $240,434 |
| Repatha SureclickEvolocumab | 99 | $103,258 |
| XareltoRivaroxaban | 49 | $69,817 |
| EntrestoSacubitril/Valsartan | 49 | $65,941 |
| Praluent PenAlirocumab | 41 | $47,174 |
| JardianceEmpagliflozin | 35 | $46,394 |
| Repatha SyringeEvolocumab | 13 | $11,606 |
| Ezetimibe | 417 | $9,587 |
| NexletolBempedoic Acid | 13 | $6,533 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $5,269 |
| Rosuvastatin Calcium | 373 | $4,968 |
| Atorvastatin Calcium | 381 | $3,679 |
| Losartan Potassium | 210 | $2,246 |
| Metoprolol Succinate | 157 | $1,997 |
| Ranolazine ErRanolazine | 11 | $1,735 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $700 | $240,434198 claims |
| Johnson & JohnsonXarelto | $493 | $69,81749 claims |
| NovartisEntresto | $357,945 | $65,94149 claims |
| Boehringer IngelheimJardiance | $7,472 | $46,39435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Overland Park
- Vasvi SinghOverland Park$436K
- Lloyd StahlOverland Park$275K
- Theodore PopeOverland Park$94K
- Rachel SoslandOverland Park$33K
- James MarcumOverland Park$30K
- Ahmed ElballatOverland Park$22K
- Arnold PollakOverland Park$18K
- Paul NagerOverland Park$10K
- Ronnie SmallingOverland Park$9K
- van JonesOverland Park$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.